retatrutide clinical trial south africa ESC 2024: improves lipid and cardiovascular risk profile in Phase II SA regulators battle to stem

Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025

Zip codes also play a significant role in determining the price of medication

Administration considerations also influence purchasing decisions

Because of this, it is a potent tool for managing type 2 diabetes, especially in people who have trouble with insulin resistance

The FDA's standard review period for a Priority Review designation is six months

Side effects are minimal